Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 3
2008 1
2009 2
2011 2
2012 2
2013 1
2014 2
2015 2
2016 6
2017 10
2018 2
2019 8
2020 6
2021 15
2022 9
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Results by year

Filters applied: . Clear all
Page 1
NASH limits anti-tumour surveillance in immunotherapy-treated HCC.
Pfister D, Núñez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, Gupta R, Qiu M, Deczkowska A, Weiner A, Müller F, Sinha A, Friebel E, Engleitner T, Lenggenhager D, Moncsek A, Heide D, Stirm K, Kosla J, Kotsiliti E, Leone V, Dudek M, Yousuf S, Inverso D, Singh I, Teijeiro A, Castet F, Montironi C, Haber PK, Tiniakos D, Bedossa P, Cockell S, Younes R, Vacca M, Marra F, Schattenberg JM, Allison M, Bugianesi E, Ratziu V, Pressiani T, D'Alessio A, Personeni N, Rimassa L, Daly AK, Scheiner B, Pomej K, Kirstein MM, Vogel A, Peck-Radosavljevic M, Hucke F, Finkelmeier F, Waidmann O, Trojan J, Schulze K, Wege H, Koch S, Weinmann A, Bueter M, Rössler F, Siebenhüner A, De Dosso S, Mallm JP, Umansky V, Jugold M, Luedde T, Schietinger A, Schirmacher P, Emu B, Augustin HG, Billeter A, Müller-Stich B, Kikuchi H, Duda DG, Kütting F, Waldschmidt DT, Ebert MP, Rahbari N, Mei HE, Schulz AR, Ringelhan M, Malek N, Spahn S, Bitzer M, Ruiz de Galarreta M, Lujambio A, Dufour JF, Marron TU, Kaseb A, Kudo M, Huang YH, Djouder N, Wolter K, Zender L, Marche PN, Decaens T, Pinato DJ, Rad R, Mertens JC, Weber A, Unger K, Meissner F, Roth S, Jilkova ZM, Claassen M, Anstee QM, Amit I, Knolle P, Becher B,… See abstract for full author list ➔ Pfister D, et al. Among authors: lujambio a. Nature. 2021 Apr;592(7854):450-456. doi: 10.1038/s41586-021-03362-0. Epub 2021 Mar 24. Nature. 2021. PMID: 33762733 Free PMC article.
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma.
Zhu AX, Abbas AR, de Galarreta MR, Guan Y, Lu S, Koeppen H, Zhang W, Hsu CH, He AR, Ryoo BY, Yau T, Kaseb AO, Burgoyne AM, Dayyani F, Spahn J, Verret W, Finn RS, Toh HC, Lujambio A, Wang Y. Zhu AX, et al. Among authors: lujambio a. Nat Med. 2022 Aug;28(8):1599-1611. doi: 10.1038/s41591-022-01868-2. Epub 2022 Jun 23. Nat Med. 2022. PMID: 35739268
Immunoediting instructs tumor metabolic reprogramming to support immune evasion.
Tsai CH, Chuang YM, Li X, Yu YR, Tzeng SF, Teoh ST, Lindblad KE, Di Matteo M, Cheng WC, Hsueh PC, Kao KC, Imrichova H, Duan L, Gallart-Ayala H, Hsiao PW, Mazzone M, Ivanesevic J, Liu X, de Visser KE, Lujambio A, Lunt SY, Kaech SM, Ho PC. Tsai CH, et al. Among authors: lujambio a. Cell Metab. 2023 Jan 3;35(1):118-133.e7. doi: 10.1016/j.cmet.2022.12.003. Cell Metab. 2023. PMID: 36599297 Free PMC article.
β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma.
Ruiz de Galarreta M, Bresnahan E, Molina-Sánchez P, Lindblad KE, Maier B, Sia D, Puigvehi M, Miguela V, Casanova-Acebes M, Dhainaut M, Villacorta-Martin C, Singhi AD, Moghe A, von Felden J, Tal Grinspan L, Wang S, Kamphorst AO, Monga SP, Brown BD, Villanueva A, Llovet JM, Merad M, Lujambio A. Ruiz de Galarreta M, et al. Among authors: lujambio a. Cancer Discov. 2019 Aug;9(8):1124-1141. doi: 10.1158/2159-8290.CD-19-0074. Epub 2019 Jun 11. Cancer Discov. 2019. PMID: 31186238 Free PMC article.
Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications.
Martin-Serrano MA, Kepecs B, Torres-Martin M, Bramel ER, Haber PK, Merritt E, Rialdi A, Param NJ, Maeda M, Lindblad KE, Carter JK, Barcena-Varela M, Mazzaferro V, Schwartz M, Affo S, Schwabe RF, Villanueva A, Guccione E, Friedman SL, Lujambio A, Tocheva A, Llovet JM, Thung SN, Tsankov AM, Sia D. Martin-Serrano MA, et al. Among authors: lujambio a. Gut. 2023 Apr;72(4):736-748. doi: 10.1136/gutjnl-2021-326514. Epub 2022 May 18. Gut. 2023. PMID: 35584893 Free PMC article.
Monocyte depletion enhances neutrophil influx and proneural to mesenchymal transition in glioblastoma.
Chen Z, Soni N, Pinero G, Giotti B, Eddins DJ, Lindblad KE, Ross JL, Puigdelloses Vallcorba M, Joshi T, Angione A, Thomason W, Keane A, Tsankova NM, Gutmann DH, Lira SA, Lujambio A, Ghosn EEB, Tsankov AM, Hambardzumyan D. Chen Z, et al. Among authors: lujambio a. Nat Commun. 2023 Apr 3;14(1):1839. doi: 10.1038/s41467-023-37361-8. Nat Commun. 2023. PMID: 37012245 Free PMC article.
TRAF6 functions as a tumor suppressor in myeloid malignancies by directly targeting MYC oncogenic activity.
Muto T, Guillamot M, Yeung J, Fang J, Bennett J, Nadorp B, Lasry A, Redondo LZ, Choi K, Gong Y, Walker CS, Hueneman K, Bolanos LC, Barreyro L, Lee LH, Greis KD, Vasyliev N, Khodadadi-Jamayran A, Nudler E, Lujambio A, Lowe SW, Aifantis I, Starczynowski DT. Muto T, et al. Among authors: lujambio a. Cell Stem Cell. 2022 Feb 3;29(2):298-314.e9. doi: 10.1016/j.stem.2021.12.007. Epub 2022 Jan 18. Cell Stem Cell. 2022. PMID: 35045331 Free PMC article.
Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation.
Zhang Z, Zhou C, Li X, Barnes SD, Deng S, Hoover E, Chen CC, Lee YS, Zhang Y, Wang C, Metang LA, Wu C, Tirado CR, Johnson NA, Wongvipat J, Navrazhina K, Cao Z, Choi D, Huang CH, Linton E, Chen X, Liang Y, Mason CE, de Stanchina E, Abida W, Lujambio A, Li S, Lowe SW, Mendell JT, Malladi VS, Sawyers CL, Mu P. Zhang Z, et al. Among authors: lujambio a. Cancer Cell. 2020 Apr 13;37(4):584-598.e11. doi: 10.1016/j.ccell.2020.03.001. Epub 2020 Mar 26. Cancer Cell. 2020. PMID: 32220301 Free PMC article.
WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma.
Rialdi A, Duffy M, Scopton AP, Fonseca F, Zhao JN, Schwarz M, Molina-Sanchez P, Mzoughi S, Arceci E, Abril-Fornaguera J, Meadows A, Ruiz de Galarreta M, Torre D, Reyes K, Lim YT, Rosemann F, Khan ZM, Mohammed K, Wang X, Yu X, Lakshmanan M, Rajarethinam R, Tan SY, Jin J, Villanueva A, Michailidis E, De Jong YP, Rice CM, Marazzi I, Hasson D, Llovet JM, Sobota RM, Lujambio A, Guccione E, Dar AC. Rialdi A, et al. Among authors: lujambio a. Nat Cancer. 2023 Aug;4(8):1157-1175. doi: 10.1038/s43018-023-00609-9. Epub 2023 Aug 3. Nat Cancer. 2023. PMID: 37537299 Free PMC article.
77 results